How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

10,329 results for

E/M Medical Decision Making

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

10241. Incorporating considerations of resources use into grading recommendations Full Text available with Trip Pro

Alessandro A Vist Gunn E GE Schünemann Holger J HJ GRADE Working Group eng Journal Article Research Support, Non-U.S. Gov't Review England BMJ 8900488 0959-8138 AIM IM BMJ.2008 Jun 21;336(7658): doi:10.1136/bmj.a403 Costs and Cost Analysis Decision Making Evidence-Based Medicine Health Planning Guidelines Health Resources economics statistics & numerical data Models, Economic Quality Assurance, Health Care 11 Alderson Phil P Alonso-Coello Pablo P Andrews Jeff J Atkins David D Bastian Hilda H de Beer Hans (...) Incorporating considerations of resources use into grading recommendations 18497416 2008 06 04 2018 12 01 1756-1833 336 7654 2008 May 24 BMJ (Clinical research ed.) BMJ Incorporating considerations of resources use into grading recommendations. 1170-3 10.1136/bmj.39504.506319.80 Guyatt Gordon H GH Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada L8N 3Z5. guyatt@mcmaster.ca Oxman Andrew D AD Kunz Regina R Jaeschke Roman R Helfand Mark M Liberati

2008 BMJ : British Medical Journal

10242. Perinatal care at an extremely low gestational age (22–25 weeks). An Italian approach: the “Carta di Firenze” Full Text available with Trip Pro

Scarselli Gianfranco G Barberi Ignazio I Barni Mauro M Bevilacqua Giulio G Branconi Francesco F Bucci Giovanni G Campogrande Mario M Curiel Pietro P Di Iorio Romolo R Di Renzo Gian Carlo GC Di Tommaso Mariarosaria M Moscarini Massimo M Norelli Gian Aristide GA Pagni Aldo A Panti Antonio A Pela Ivana I Rondini Giorgio G Saggese Giuseppe G Salvioli Giampaolo G Scarano Enrico E Donzelli Gianpaolo G eng Consensus Development Conference Journal Article Practice Guideline England Arch Dis Child Fetal Neonatal (...) Ed 9501297 1359-2998 AIM IM Decision Making Female Gestational Age Humans Infant, Newborn Infant, Premature Italy Perinatal Care Pregnancy Pregnancy Trimester, Second Premature Birth 15 2007 10 24 9 0 2007 12 12 9 0 2007 10 24 9 0 ppublish 17951554 92/6/F515 10.1136/adc.2007.119446 PMC2675411 Arch Pediatr. 2001 Apr;8(4):407-19 11339134 Obstet Gynecol. 2002 Sep;100(3):617-24 12220792 Pediatrics. 2002 Nov;110(5):1024-7 12415047 BJOG. 2006 Dec;113 Suppl 3:13-6 17206961 J Gynecol Obstet Biol Reprod

2007 Archives of Disease in Childhood. Fetal and Neonatal Edition

10243. Postpartum Haemorrhage

for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our . Our clinical information is certified to meet NHS England's Information Standard. Health information you can trust Patient aims to help the world proactively manage its healthcare, supplying evidence-based (...) Postpartum Haemorrhage Postpartum Haemorrhage. PPH Condition information | Patient TOPICS Try our Symptom Checker TREATMENT RESOURCES Try our Symptom Checker PROFESSIONAL Upgrade to Patient Pro / / Search Postpartum Haemorrhage Authored by , Reviewed by | Last edited 2 Jan 2015 | Certified by This article is for Medical Professionals Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European

2008 Mentor

10244. Major Incident Plans

. There are two mnemonics to help with this. They are METHANE and CHALETS and the contents are similar: M ajor incident declared. E xact location. T ype of incident - eg, explosion and fire in a tall building, release of gas in the underground system. H azards - present and potential. A ccess - routes that are safe to use. N umber, type, severity of casualties. E mergency services now present and those required. C asualties - number, type, severity. H azards present. A ccess routes that are safe to use. L (...) surgeon. The command and control centre will probably not be in A&E, as it will be extremely busy there. Careful and systematic assessment of non-critical patients already in hospital for early discharge can be used to make hospital beds available for victims of a mass emergency. This is called reverse triage. A&E - the non-casualties There will be the usual flow of patients from unrelated events in A&E. Someone has to deal with them or send them elsewhere. This may be to another hospital or asking

2008 Mentor

10245. Ankle Injuries

. You may find the article more useful, or one of our other . In this article In This Article Ankle Injuries In this article See also separate article. Ankle injuries are common in primary care, A&E and sports medicine. Most are inversion and plantar flexion injuries that lead to damage to the lateral ligaments. [ ] The ankle is a complex joint which is capable of a wide range of movement: flexion, extension, inversion and eversion as well as a combination of these movements. This allows locomotion (...) clinicians. Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our . Our clinical information is certified to meet NHS England's Information Standard. Health information you can trust Patient

2008 Mentor

10246. Breaking Bad News

disclosure and decision-making: the Middle East versus the Far East and the West. J Med Ethics. 2008 Apr34(4):225-9. doi: 10.1136/jme.2006.019638. ; Macmillan Cancer Support ; General Medical Council ; British Geriatrics Society (2011) ; guidance on how to support people with learning (intellectual) disabilities in bad news situations ; National Patient Safety Agency Best Practice Guide (19 November 2009) Sorry all of u i m writing here again. No one dr or cardiologist understanding me. I m laying (...) news are now a core part of the medical school curriculum. Poor communication, particularly with cancer patients, has been shown to be associated with worse clinical and psychosocial outcomes, including worse pain control, worse adherence to treatment, confusion over prognosis and dissatisfaction at not being involved in decision making. [ ] For the clinician, communication difficulties lead to worse job satisfaction and higher stress levels, as well as being behind a high proportion of errors

2008 Mentor

10247. Venous Thromboembolism In Pregnancy

of therapy have been completed. At that point, the patient should be assessed for the presence of ongoing risk factors for a VTE prior to making the decision to stop anticoagulation therapy. Complications Thrombophilia and placental vascular complications Fetal loss : although the figures are likely to be small (there are not many studies), there is thought to be a doubling of risk of fetal loss in women with genetic thrombophilia. : a specific association between this and thrombophilia has not been (...) (v24) Author Peer reviewer Dr John Cox The information on this page is written and peer reviewed by qualified clinicians. Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our . Our

2008 Mentor

10248. Genetic Counselling for GPs

consent. In situations where testing children or other persons who are not able to give informed consent is considered, those individuals should be involved in genetic counselling and in the decision-making process, according to their capacities. Testing for adult-onset conditions in children should only be considered when treatment or surveillance would begin in childhood. Pre-test genetic counselling Individuals are informed about the purpose of the test, including: Up-to-date, reliable description (...) be offered when available. A written summary of the discussion should be offered. European guidelines on genetic counselling for pre-symptomatic testing have been developed. These include general principles governing the offer of testing (eg, autonomous choice of the patient), objectives of genetic counselling in this context (eg, facilitation of decision making), logistical considerations (eg, use of trained staff) and topics to be included during counselling discussion with the patient (eg

2008 Mentor

10249. Obstetric Shock

for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our . Our clinical information is certified to meet NHS England's Information Standard. Health information you can trust Patient aims to help the world proactively manage its healthcare, supplying evidence-based (...) Obstetric Shock Postpartum Haemorrhage. PPH Condition information | Patient TOPICS Try our Symptom Checker TREATMENT RESOURCES Try our Symptom Checker PROFESSIONAL Upgrade to Patient Pro / / Search Postpartum Haemorrhage Authored by , Reviewed by | Last edited 2 Jan 2015 | Certified by This article is for Medical Professionals Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines

2008 Mentor

10250. Obesity in Adults

to the individual; their overall health and fitness, preferences, beliefs, and lifestyle. History Ask: "Why do you want to lose weight?" The response may give an indication of motivation. Explore the person's view of their weight, and the reason they have gained weight. Explore eating behaviour. Explore beliefs about eating patterns, exercise patterns and weight. Explore past medical history, including history of dieting. Find out what has been successful or otherwise in the past. Assess readiness to make (...) change, and confidence in making changes. Assess for any physical or psychological problems associated with obesity. Assess for comorbidity: diabetes, hypertension, cardiovascular disease, dyslipidaemia, sleep apnoea, osteoarthritis. Social history, including diet, exercise, occupation, smoking. Family history, including history of obesity, diabetes, heart disease. Medication which may aggravate weight gain [ ] Oral hypoglycaemic agents, especially sulfonylureas and thiazolidinediones ("glitazones

2008 Mentor

10251. Osteoporosis Case Finding in Primary Care

with osteoporosis. The European Medicines Agency (EMA) advised that it only be used where other medications are not tolerated and there are few cardiovascular risk factors [ ] . Clinical Editor's comments (September 2017) Dr Hayley Willacy reads that the manufacturer has decided to withdraw strontium worldwide because the number of patients treated with the drug declined. GPs are advised to identify and review any patients who are currently prescribed strontium ranelate and discuss alternative treatment options (...) 1613 (v31) Author Peer reviewer Dr John Cox The information on this page is written and peer reviewed by qualified clinicians. Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our

2008 Mentor

10252. Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML

Frame: 6 months ] Cenersen plus standard of care Secondary Outcome Measures : Determine the safety profile for the combination of EL625 and Idarubicin +/- Cytarabine. [ Time Frame: 6 months ] Standard of care plus cenersen Determine the Complete Response Rate and Time to Progression. [ Time Frame: 6 months ] Standard of care plus cenersen Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your (...) antioxidants (e.g., Vitamins C, E; Multivitamins) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00074737 Locations Layout table for location information United States, California University of California, San Diego La Jolla, California, United States

2003 Clinical Trials

10253. Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment Naive Adults With Chronic Hepatitis B Virus Infection

condition or prior therapy that, in the Investigators opinion, would make the subject unsuitable for the study or unable to comply with the dosing requirements Use of any investigational drug. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00034359 (...) Official Title: A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults Study Start Date : February 2002 Actual Primary Completion Date : January 2003 Actual Study Completion Date : January 2003 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine

2002 Clinical Trials

10254. A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas

annually, and when clinically indicated. Baseline MR images are compared with MR images performed during the various cycles (e.g. cycles 1, 2, 3...) Imaging was exploratory and the degree of change that is considered clinically significant rather than technique related is still being explored. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about (...) Results First Posted : February 13, 2012 Last Update Posted : February 13, 2012 Sponsor: National Cancer Institute (NCI) Information provided by: National Institutes of Health Clinical Center (CC) Study Details Study Description Go to Brief Summary: Diffuse pontine gliomas are tumors on the pons portion of the brainstem. Their peak incidence is in children between 5 and 10 years old. Their location makes surgical resection impossible. Most patients are treated with radiation, which typically delays

2002 Clinical Trials

10255. Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

and -Experienced HIV-Infected Infants, Children, and Adolescents Study Start Date : November 2000 Actual Primary Completion Date : October 2011 Actual Study Completion Date : September 2014 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Step I: Group 1 Group 1 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder) and two NRTIs. ATV Dose Tested: 310 mg/m^2, 620 (...) mg/m^2; Final Dose: Not Established Drug: ATV Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in. Experimental: Step I: Group 2 Group 2 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder) and two NRTIs. ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established Drug

2000 Clinical Trials

10256. Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: up to 69 Years (Child, Adult, Older Adult) Sexes Eligible for Study: All (...) system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving immunosuppressive therapy after the transplant may stop this from happening. PURPOSE: This phase II trial is studying how well donor bone marrow or peripheral stem cell transplant

2003 Clinical Trials

10257. Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma

the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: up to 69 Years (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers (...) . It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well fludarabine and cyclophosphamide followed by peripheral stem cell transplant works in treating patients with leukemia or lymphoma. Condition or disease Intervention/treatment Phase Leukemia

2000 Clinical Trials

10258. Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

. [ Time Frame: From baseline to completion of hormone therapy ] Secondary Outcome Measures : Changes in histology and ultrasound appearance of the endometrium in women with HNPCC [ Time Frame: From baseline to 3 months ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may (...) tobacco smoker Known inability to participate in the scheduled follow-up tests (i.e., alcohol dependence or illicit drug use) Significant medical history or psychiatric problems which would make the participant a poor protocol candidate, in the opinion of the principal investigator Post surgical removal of both ovaries Postmenopausal women with amenorrhea greater than 12 months Previous history of endometrial biopsy, hysteroscopy, dilatation and curettage, or IUD in place within the past 3 months

2002 Clinical Trials

10259. Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

topics: resources: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible (...) : Eastern Cooperative Oncology Group Collaborator: National Cancer Institute (NCI) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies such as sargramostim and interferon alfa use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known if vaccine therapy if more effective with or without biological

2000 Clinical Trials

10260. Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

responses as assessed by elispot and tetramer staining at every visit Time to progression as assessed by clinical staging (CT scan and PET) every 3 months Objective response rate as assessed by clinical staging (CT scan and PET) every 3 months Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study (...) , Schierer S, Beltrame L, Theiner G, Zinser E, Ostalecki C, Heidkamp G, Haendle I, Erdmann M, Wiesinger M, Leisgang W, Gross S, Pommer AJ, Kämpgen E, Dudziak D, Steinkasserer A, Cavalieri D, Schuler-Thurner B, Schuler G. Identifier: DOI:10.1182/blood-2012-09-4569 Denileukin diftitox (ONTAK) induces... Baur AS et al Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: PD Dr. med. univ. Beatrice Schuler

2003 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>